Table 1 Study characteristics in Paucibacillary Leprosy
Study | Study Design | Country | Follow Up (years) | N | Age (Years) | Diagnosis | Control Used | Evaluated Outcome |
|---|---|---|---|---|---|---|---|---|
2–3 LMT, 2001 [16] | RCT | India | 1.5 | 236 | Children and adults | Clinical and bacteriologicala | ROM (single monthly dose, children were given half the dose) | -Clinical score -Lesion resolution -Tx failure |
Babu, 1997 [17] | RCT | Multicenter | 1.5 | 1483 | Mean 23.5 | Clinical and bacteriologicala | ROM (single monthly dose) | Clinical score |
Balagon, 2010 [18] | RCT | Phillipines | 12 | 124 | MDT:33.5±13.2 35.1±15.2 | NR | 28 days of RFP + ofloxacin for 4w then 5 m of placebo | -Relapse -Cure |
Bathe,1986 [19] | RCT | India | 1 | 80 | 19–45 | Clinical, bacteriological, immunological, histological | MDT + clofazimine in alternative days for 6 m | Clinical score |
Deshmuk, 2003 [20] | RCT | India | 0.5 | 32 | 23 ≦ 30 years and 9 > 30 years | Clinical and bacteriologicala | ROM (single monthly dose) | Clinical and histopathological score |
Emmanuel, 2005 [21] | RCT | India | 2 | 51 | Children and adults | Clinical and histological | ROM (single monthly dose) | Clinical score |
Katoch, 1999 [22] | RCT | India | 2 | 300 | NR | NR | MDT + clofazimine | -Active disease/signs of activity -Mitsuda reaction -Relapse |
Kumar 2015 [23] | RCT | India | 8 | 268 | Mean 38.3 | Skin lesions and nerve involvement | ROM (Single monthly dose) | Cure and relapse |
Manickam 2012 [24] | RCT | India | 3 | 1526 | Mean 27 | Skin lesions and nerve involvement | ROM (single dose, children were given half the dose) | -Clinical score -Complete clearance |
Mathai, 1991 [25] | RCT | India | 2 | 54 | 7–67 | NR | MDT + dapsone | Mitsuda reaction |
Orege, 1990 [26] | RCT | Kenya | 0.6 | 127 | NR | Clinical | MDT + RFP + dapsone | Clinical score |
Rao, 2009 [27] | Not randomized | India | 2 | 32 | NR | Clinical | RFP + dapsone + clofazimine × 6 m | Clinical and histopathological score |